Trials / Recruiting
RecruitingNCT07123727
A Study to Examine Anktiva for the Treatment of COVID-19.
Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- ImmunityBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anktiva | 600ug of NAI administered subcutaneously |
Timeline
- Start date
- 2025-09-04
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2025-08-14
- Last updated
- 2025-10-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07123727. Inclusion in this directory is not an endorsement.